Efficacy of a strategy for discontinuing pre-emptive ganciclovir therapy after a negative cytomegalovirus antigenaemia test result in seropositive kidney transplant recipients

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 5, 2013, Pages 1209-1211

  Park, So Youn ^a   Kim, Young Hoon ^a   Han, Duck Jong ^a   Park, Su Kil ^a   Park, Jung Sik ^a   Sung, Heungsup ^a   Park, Hyun Jung ^a   Kim, Sung Han ^a   Choi, Sang Ho ^a   Kim, Yang Soo ^a   Woo, Jun Hee ^a   Lee, Sang Oh ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

CMV; Kidney transplantation; Pre emptive therapy

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GANCICLOVIR; VALGANCICLOVIR; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; CLINICAL EFFECTIVENESS; COLITIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG WITHDRAWAL; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; KIDNEY TRANSPLANTATION; LETTER; LEUKOPENIA; LUNG ASPERGILLOSIS; MEDICAL RECORD REVIEW; PATIENT MONITORING; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RECURRENCE RISK; RELAPSE; SEPTIC SHOCK; SERODIAGNOSIS; SURGICAL INFECTION; TREATMENT DURATION; VIRAL CLEARANCE; VIREMIA;

ADULT; ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TIME FACTORS; TRANSPLANTATION;

EID: 84877100663     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks524     Document Type: Letter

References (10)

1. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S78-86.
2. Andrews PA, Emery VC, Newstead C. Summary of the British Transplantation Society guidelines for the prevention and management of CMV disease after solid organ transplantation. Transplantation 2011; 92: 1181-7.
3. Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-95.
4. Park SY, Lee SO, Choi SH et al. Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study. J Antimicrob Chemother 2012; 67: 1486-92.
5. Kim T, Sung H, Park KT et al. Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation. Infect Chemother 2009; 41: 72-7.
6. Humar A, Kumar D, Boivin G et al. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186: 829-33.
7. Sia IG, Wilson JA, Groettum CM et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181: 717-20.
8. Meyer-Koenig U, Weidmann M, Kirste G et al. Cytomegalovirus infection in organ-transplant recipients: diagnostic value of pp65 antigen test, qualitative polymerase chain reaction (PCR) and quantitative Taqman PCR. Transplantation 2004; 77: 1692-8.
9. Emery VC, Hassan-Walker AF, Burroughs AK et al. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis 2002; 185: 1723-8.
10. Emery VC, Sabin CA, Cope AV et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-6.